Plant Name: Piper umbellatum
Taxonomic Information:
Plant ID: NPO18911
Plant Latin Name: Piper umbellatum
Taxonomy Genus: Piper
Taxonomy Family: Piperaceae
Plant External Links:
NCBI TaxonomyDB:
130418
Plant-of-the-World-Online:
316339-2
Used in Medicines:
Country/Region:
Ghana; Kenya; Tanzania; Rwanda; ChinaTraditional Medicine System:
TCMGeographical Distribution:
Brazil; Sudan; Guinea; Costa Rica; Ethiopia; Rwanda; Peru; Nigeria; Bolivia; Cameroon; Cote d'Ivoire; Ecuador; Ghana; Cuba; Venezuela; Malawi; Togo; Zimbabwe; China; Haiti; Belize; Sierra Leone; Liberia; Uganda; Tanzania; Mauritius; Trinidad and Tobago; Gabon; Honduras; Dominican Republic; Jamaica; Seychelles; Angola; Mexico; Congo; Mozambique; Colombia; Burundi; Kenya
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; | |
| GAA; | |
| CA2; CA1; CA7; CA4; CA6; CA12; CA9; CA14; | |
| NR1H4; | |
| MAOA; | |
| AKR1B10; | |
| MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.282E-08 | 4.969E-05 | CA1, CA12, CA2, CA4, CA6, CA7, CA9, NR1H4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.463E-06 | 2.124E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.463E-06 | 2.124E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.463E-06 | 2.124E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 7.305E-06 | 8.372E-03 | CA1, CA2 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.019E-23 | 8.751E-19 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.098E-18 | 1.195E-14 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.428E-16 | 6.217E-13 | CA1, CA12, CA2, CA4, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 2.188E-05 | 2.269E-02 | CA2, CA7 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.149E-22 | 3.101E-21 | CA12, CA1, CA2, CA4, CA7, CA6, CA9, CA14 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.142E-04 | 1.541E-03 | CA2, CA4 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 1.957E-04 | 1.762E-03 | AKR1B10, GAA |
| 09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.100E-03 | 7.425E-03 | CA2, NR1H4 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00350 | Tyrosine metabolism | 2.423E-02 | 6.221E-02 | MAOA |
| 09150 Organismal Systems | 09155 Excretory system | hsa04966 | Collecting duct acid secretion | 1.874E-02 | 6.221E-02 | CA2 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00040 | Pentose and glucuronate interconversions | 2.492E-02 | 6.221E-02 | AKR1B10 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.765E-02 | 6.221E-02 | MAOA |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00260 | Glycine, serine and threonine metabolism | 2.765E-02 | 6.221E-02 | MAOA |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 2.218E-02 | 6.221E-02 | AKR1B10 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
